tbuckley/cabot-search huggingface dataset:
Atherosclerosis and Nutrition
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
General Practice
Authors: Robert M. Bucher
Journal: JAMA (1963)

<h3>To the Editor:</h3> —I can well understand Dr. Cahal's surprise, since the results of this recent survey were quite surprising to us. During the latter part of 1962, Dr. Robert Lambert of the Woman's Medical College of Pennsylvania conducted a short study of freshman and senior students in his own school and in the Temple University School of Medicine. This was done to obtain data for presentation to a hearing on licensure requirements conducted by the Pennsylvania State Board of Medical Education and Licensure. He found that 36% of the freshmen expressed an intention to enter general practice and that 33% of the seniors expressed this intention. This study, with the description of method and other detail, was presented in testimony given by Dr. Lambert to the State Board of Medical Education and Licensure on Nov 28, 1962, and appears in the transcript of that hearing. It is of some
Percutaneous coronary intervention mortality measures: In-hospital, thirty-day and procedural Daniel J. O'Rourke, David J. Malenka, David E. Wennberg, Samuel J. Shubrooks, Mirle A. Kellett, Jr., Matthew W. Watkins, William A. Bradley, Peter N. Ver Lee, Michael A. Hearne, Bruce D. Hettleman, The Northern New England Cardiovascular Disease Study Group. Dartmouth-Hitchcock Medical Center, Lebanon, NH, Veterans Affairs, White River Junction, VT
Journal: Journal of the American College of Cardiology (2001)
The smoker's paradox: Angiographic insights from the TIMI trials Sarah R. Kermgard, Michael S. Chen, Sabina A. Murphy, Jessica S. Lim, Colin A. Hynes, Matthew H. C. Otten, Lily L. Luu, Susan J. Marble, Christopher P. Cannon, Eugene Braunwald, C. Michael Gibson. University of California San Francisco, San Francisco, CA, Brigham and Women's Hospital, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
Offline: How others see us
Authors: Richard Horton
Journal: The Lancet (2021)

"A victory for science!" Who could possibly disagree with Christel van Geet, Vice-Rector of Biomedical Sciences at the University of Leuven? She was opening a symposium about the defence of rationality during the COVID-19 pandemic, held at the University of Sorbonne, Paris, last week. Jean-François Delfraissy, President of France's COVID-19 Scientific Council, called COVID-19 vaccines a "miracle". The Rector of the University of Geneva, Yves Flückiger, described the contribution of science to the pandemic as "spectacular".
P941 – P1197
Authors: I Pachiadakis, V Karavassilis, A Vasdeki, A Melidou, A Goudouva, P Lisgara, E Petinaki, A Maniatis, C Savin, S Huck, C Rolland, M Benderdouche, O Faure, G Noacco, J Menotti, E Candolfi, H Pelloux, R Grillot, F Derouin, S Coupe, S Grzeszczuk, A Sabat, M Bartoszewicz, C Aldea-Mansilla, D Garcı ´a De Viedma, E Cercenado, E Bouza, M Ma, V Meroni, F Genco, G Ferraris, L Bollani, L Piccoli, C Bodini, P Lanzarini, W Yu, K Nielsen, T Grushina, T Meka, A Kerttula, A Vainio, S Mero, T Pasanen, J Vuopio-Varkila
Journal: Clinical Microbiology and Infection (2006)
LONDON
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Troponin I release pattern and myocardial dysfunction after high-dose chemotherapy Daniela Cardinale, Maria Teresa Sandri, Alessandro Martinoni, Alessio Tricca, Elena Borghini, Maurizio Civelli, Giuseppina Lamantia, Giovanni Martinelli, Cesare Fiorentini, Carlo M. Cipolla. Istituto Europeo di Oncologia, Milan, Italy
Journal: Journal of the American College of Cardiology (2001)
Terminological Logic
Authors: Samuel Vaisrub
Journal: JAMA (1977)

Although it is more blessed to give than to receive, dictionaries have bestowed a larger measure on receiving than giving. In contrast to the paucity of derivatives of<i>donare</i>(Latin, to give) is the abundance of words derived from<i>recipere</i>(Latin, to receive). The nouns alone—"receiver," "receptionist," "receptacle," "recipient," "reception," "recipience"—fill a dictionary column. When nearly a century ago Ehrlich added "receptor" to the prolific progeny of<i>recipere</i>, he applied the term to hypothetical "side-chains" with affinities for a specific toxin. If present in excess, these chains would become detached from the cell to circulate freely in the blood where they could render the toxin harmless by combining with it. Ehrlich's side-chain theory is almost forgotten, but the concept of receptors with an affinity for specific substances has been greatly expanded and translated into reality. The specific substances need not be extrinsic antigens or drugs. They can be endogenous hormones.
Ultraviolet Cystoscopy
Authors: Willet F. Whitmore
Journal: JAMA (1968)

It is well recognized that the actual onset of malignant change may antedate by a considerable time the first identifiable morphologic manifestations of neoplasm and that the latter in turn may precede the first symptomatic manifestations of the process. Even after the appearance of symptoms, the interval before the specific diagnosis is accurately made may be long—a possibility for which the site and nature of the malignant change, the patient, and the physician share varying degrees of responsibility. Furthermore, the presence of a clinically obvious neoplasm at one site in a tissue or organ is often associated with an increased probability of coexistent neoplastic change at other sites in the respective organ or tissue. These generalizations relative to tumor behavior have specific application in the case of neoplasms of the human bladder. The possibility that cancer of the bladder may have a preclinical phase has been overshadowed by the facts
Public Health Service Recommendations for the Use of Vaccines Manufactured With Bovine-Derived Materials
Journal: JAMA (2001)

EMERGENCY DEPARTMENT (ED) STAFF caring for patients contaminated with toxic chemicals are at risk for developing toxicity from secondary contamination.This report describes three cases of occupational illnesses associated with organophosphate toxicity caused by exposure to a contaminated patient and underscores the importance of using personal protection equipment (PPE) and establishing and following decontamination procedures in EDs and other areas of acute care hospitals.
Antibodies to human heat shock protein 60 are associated with presence and severity of coronary artery disease Jianhui Zhu, Arshed A. Quyyumi, David Rott, Hongsheng Wu, Julian P. J. Halcox, Stephen E. Epstein. Washington Hospital Center, Washington, DC, NHLBI, NIH, Bethesda, MD
Journal: Journal of the American College of Cardiology (2001)
Error in Main Text
Authors: Sarah Ferguson, Kathleen Meert
Journal: JAMA Surgery (2021)

Olle Ljungqvist, MD, PhD; Hans D. de Boer, MD, PhD; Angie Balfour, RN, MSc; William J. Fawcett, MBBS; Dileep N. Lobo, MS, DM; Gregg Nelson, MD, PhD; Michael J. Scott, MB, ChB; Thomas W. Wainwright, BSc, MCSP; Nicolas Demartines, MD
LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INCIDENT CORONARY HEART DISEASE AMONG WHITES IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY
Authors: Lisandro Colantonio, Michael Miller, Maciej Banach, Robert Rosenson, Monika Safford, Sergio Fazio, Paul Muntner, Peter Toth
Journal: Journal of the American College of Cardiology (2016)
Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections
Authors: Yiyun Zhu, Weijing Hao, Xia Wang, Jianhong Ouyang, Xinyi Deng, Haining Yu, Yipeng Wang
Journal: Medicinal Research Reviews (2022)

Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlikely. Therefore, they have great potential as new generation antimicrobial agents. To date, more than 30 AMP-related drugs are in the clinical trial phase. In recent years, studies show that some AMPs and conventional antibiotics have synergistic effects. The combined use of AMPs and antibiotics can kill drug-resistant pathogens, prevent drug resistance, and significantly improve the therapeutic effects of antibiotics. In this review, we discuss the progress in synergistic studies on AMPs and conventional antibiotics. An overview of the current understanding of the functional scope of AMPs, ongoing clinical trials, and challenges in the development processes are also presented.
Society of Thoracic Radiology—Annual Postgraduate Course
Journal: JNCI Journal of the National Cancer Institute (1987)

Society of Thoracic Radiology—Annual Postgraduate Course JNCI: Journal of the National Cancer Institute, Volume 79, Issue 4, October 1987, Page 909, https://doi.org/10.1093/jnci/79.4.909-f Published: 01 October 1987
Diffusion-magnetic resonance imaging predicts decline of kidney function in chronic kidney disease and in patients with a kidney allograft
Authors: Lena Berchtold, Lindsey A. Crowe, Christophe Combescure, Miklos Kassaï, Ibtisam Aslam, David Legouis, Solange Moll, Pierre-Yves Martin, Sophie de Seigneux, Jean-Paul Vallée
Journal: Kidney International (2022)
Letter to the Editor: Lapatinib Confounds Post-Hoc Weight Loss Analysis in the ALTTO Trial
Authors: Neil M. Iyengar, Jennifer A. Ligibel
Journal: Journal of the National Comprehensive Cancer Network (2022)

We read with particular interest the article by Martel et al 1 exploring associations between obesity, weight change, and survival in patients with HER2-positive early breast cancer in the ALTTO trial.The authors main findings were 2-fold: (1) obesity at randomization was associated with worse distant disease-free survival (DDFS) and overall survival (OS), and (2) weight loss $5% at 2 years after randomization was associated with poorer DFS, DDFS, and OS.Although the first finding is consistent with previously published metaanalyses, 2 we have concerns regarding the authors' discussion of the second result and believe a more thorough explanation is warranted to minimize misinterpretations that could negatively impact clinical recommendations.The authors noted that intentional versus unintentional weight loss would have been informative for this study, but was unavailable.We wanted to clarify that not differentiating between how weight loss was achieved is a crucial missing data point that ultimately obscures their conclusion.Weight loss after diagnosis among patients with breast cancer, induced by healthy diet and exercise, has favorably impacted treatment-related adverse effects, quality of life, body composition measures, and serum inflammatory and
Reply
Authors: Sarah Wang, Reid Whitlock, Jennifer C. Lai, Sunil Taneja, Puneeta Tandon
Journal: Hepatology (2022)

We thank Dr. Singh et al. for their insightful comments on the role of ethnicity/race and sex in the measurement of frailty. We applaud their efforts in deriving a Liver Frailty Index (LFI) cutoff specific to the Indian population and look forward to seeing the publication of those results. In the current series, we acknowledge that the LFI was derived in a predominantly Caucasian population, while our cohort consisted of 20% Asian patients. We are grateful for this opportunity to address a few observations noted by Singh and colleagues. First, contrary to what is presented in the letter by Singh et al., we would like to clarify that out of the 170 Asian patients in our cohort, 60 were frail (35%), compared to the 578 Caucasian/European patients, where 125 were frail (22%). The prevalence of frailty in the Asian cohort is similar to that of other races (Native/Aboriginal, 12 out of 40 [30%], other, 4 out of 11 [36%]) and within range of what is currently reported in the literature.[1] Singh et al. describe a prevalence of frailty of 59% in Indian patients awaiting liver transplantation, while our cohort included all outpatients with cirrhosis, including those not actively on the waitlist. Acknowledging that cutoff values may vary by ethnicity/race and sex, all our analyses for primary and secondary endpoints were also performed using the LFI as a continuous scale. With these analyses, our results remain unchanged. A 0.1 increase in the LFI was associated with an HR for death or progression of 1.05 (95% CI, 1.02–1.08) and 1.06 (95% CI, 1.04–1.08) in compensated and decompensated disease, respectively. Similarly, a 0.1 increase in the LFI was associated with an HR for death alone of 1.09 (95% CI, 1.04–1.15) and 1.08 (95% CI, 1.06–1.10) in compensated and decompensated disease, respectively. In response to Singh et al., we also ran an interaction term of Asian versus non‐Asian patients across all outcomes. The results show that there was a significant interaction between the Asian race and outcomes; however, the association of frailty with progression, death, and hospitalizations was stronger in the Asian population. Due to the small number of patients who were robust and Asian, the HRs were unstable and could not be precisely reported. Taken together, while we completely agree that ethnicity/race can play a role in cutoff values for frailty, our results remain robust after using the LFI as a continuous scale and with the Asian race as an interaction term. We look forward to further research in the area with a larger representation of the Asian population. CONFLICT OF INTEREST Nothing to report.
A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study).
Authors: Yuhong Dai, Xiongjie Yu, Huiting Xu, Liang Zhuang, Mingsheng Zhang, Yanmei Zou, Qiang Fu, Hong Qiu, Xianglin Yuan
Journal: Journal of Clinical Oncology (2022)

282 Background: Albumin-bound paclitaxel has been proven to be an active agent in advanced gastric cancer, and was approved by PMDA Japan for use as a second-line treatment of advanced gastric cancer. The aim of this study was to evaluated the efficacy and safety of AS and SOX in the first-line treatment of advanced gastric cancer. Methods: Patients diagnosed with unresectable locally advanced, recurrent or metastatic human epidermal growth factor receptor type 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma were randomized (1:1) to either AS group (albumin-bound paclitaxel 260mg/m 2 d1 or 130mg/m 2 d1, 8; S-1 40 mg [BSA &lt; 1.25 m 2 ], 50 mg [1.25 ≤ BSA &lt; 1.50 m 2 ] and 60 mg [BSA ≥1.50 m 2 ] b.i.d. d1-14, every 3wks) or SOX group (oxaliplatin 130mg/m 2 d1; S-1 40 mg [BSA &lt; 1.25 m 2 ], 50 mg [1.25 ≤ BSA &lt; 1.50 m 2 ] and 60 mg [BSA ≥1.50 m 2 ] b.i.d. d1-14, every 3wks). Primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. Results: Between March 2019 and March 2021, 96 patients were enrolled and 85 patients (AS group, n = 43; SOX group, n = 42) who received at least one dose of study drug and had at least one postbaseline efficacy evaluation were included in the final analysis. 34 (79.0%) patients in the AS group and 35 (83.3%) in the SOX group had discontinued treatment. Of these 85 patients, 78.8% had two or more organs involved, 61.2% had peritoneal dissemination, and more than 1/4 had massive ascites. Patient demographics and disease characteristics were generally balanced between arms. With median follow-up 15.4 months (95% CI, 8.8-21.9), the median PFS of AS group vs. SOX group was 9.2 vs.5.1 months (HR = 0.58 [95% CI 0.36-0.96], p = 0.034); and the median OS was 14.4 vs. 15.4 months (HR = 0.73 [95%CI 0.40-1.34], p = 0.375). Tumor response was assessable in 33 patients according to RECIST V1.1 in both cohorts, the ORR and DCR were similar in AS vs. SOX arm (ORR: 54.5% vs. 51.5%, P = 0.805; DCR: 78.8% vs. 78.8%, P = 1.000). The main grade 3 or worse treatment-related adverse events were neutropenia (30.2% vs 23.8%), Leucopenia (11.6% vs 11.9%) and peripheral sensory neuropathy (4.7% vs 7.1%) in AS and SOX group. The study was planned to be adjusted, due to the widespread use of immunotherapy in first-line treatment of gastric cancer. Conclusions: The results of this study indicated that in previously untreated patients with unresectable locally advanced, recurrent or metastatic HER2-negative gastric or GEJ adenocarcinoma, AS achieved better PFS than SOX, with an inadequate power. The toxicities were controllable and consistent with previously reported. Clinical trial information: NCT03801668.
Metastasectomy in colorectal cancer patients with concurrent lung and liver metastasis: Trends in utilization and impact on survival.
Authors: Jude Khatib, Suleyman Yasin Goksu, Sarah Reddy, Nivan Chowattukunnel, Nina Niu Sanford, Aravind Sanjeevaiah, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi
Journal: Journal of Clinical Oncology (2022)

53 Background: Colorectal cancer (CRC) frequently presents with concurrent metastasis to the lung and liver. Metastasectomy may offer extended disease control in a select group of patients but its utilization is unknown. We aimed to investigate the trends in utilization of metastasectomy in CRC patients with concurrent lung and liver metastasis and explore its impact on survival. Methods: We queried the National Cancer Database and identified stage 4 CRC patients with concurrent lung and liver metastasis between 2010 – 2016 and categorized them into those that underwent metastasectomy vs. those that did not. Categorical variables were compared using the chi-square test, and statistically significant factors were included in multivariable logistic regression analysis. In addition, 1:2 propensity score matching was performed, and a multivariable Cox regression model was used to define survival predictors among matched cohorts. The Kaplan-Meier method was used to estimate the median survival. Results: Out of total 77,719 stage 4 CRC patients, 10,106 (13.0%) patients had concurrent lung and liver metastasis. Six percent (n = 630) of these patients underwent metastasectomy of both sites. Patients that underwent metastasectomy were more likely to be younger (&lt; 50 years; p = 0.009), female ( p &lt; 0.001), and White ( p = 0.01). These patients were also more likely to have right-sided CRC ( p = 0.001) and had resection of the primary site (p &lt; 0.001). Additionally, they were more likely to have private health insurance ( p &lt; 0.001) and receive treatment at an academic center ( p = 0.03). On adjusted multivariable analysis, female gender, care at an academic center, primary tumor resection and receiving chemotherapy were associated with the metastasectomy group. We did not find a statistically significant difference between comorbidity score, KRAS status and microsatellite status between the 2 groups. In the matched analysis, overall survival (OS) was significantly improved for patients who underwent metastasectomy (23.2 months) vs. those who did not (11.6 months, p &lt; 0.001). On multivariable analysis, this difference remained, and metastasectomy was an independent predictor of better OS (HR 0.74 [0.65-0.85], p &lt; 0.001). Conclusions: The utilization of metastasectomy in concurrent lung and liver metastasis is low. It is more frequently used in younger, female and White patients, as well as in patients treated at an academic center. Metastasectomy is independently associated with improved overall survival in patients eligible for such an approach.
Hepatology Highlights
Authors: Adam Buckholz, Arun Jesudian, Tejasav S. Sehrawat, Ojasav Sehrawat, Robert E. Schwartz, Muzammil Muhammad Khan, Maria Alejandra Luna‐Cuadros, Daryl T.Y. Lau, Adebowale O. Bamidele, Anthony J. Choi, Brett E. Fortune, Petra Hirsova, Enis Kostallari, Thuy‐Van P. Hang, Preeti A. Reshamwala, Nabeel A. Wahid, Russell Rosenblatt, Nidhi Jalan‐Sakrikar
Journal: Hepatology (2021)

Buckholz, Adam; Jesudian, Arun; Sehrawat, Tejasav S.; Sehrawat, Ojasav; Schwartz, Robert E.; Muhammad Khan, Muzammil; Luna‐Cuadros, Maria Alejandra; Lau, Daryl T.Y.; Bamidele, Adebowale O.; Choi, Anthony J.; Fortune, Brett E.; Hirsova, Petra; Kostallari, Enis; Hang, Thuy‐Van P.; Reshamwala, Preeti A.; Wahid, Nabeel A.; Rosenblatt, Russell; Jalan‐Sakrikar, Nidhi Author Information
The Aphasias and their Medico-Legal Relations.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal